<DOC>
	<DOCNO>NCT00125840</DOCNO>
	<brief_summary>Clofarabine ( injection ) approve Food Drug Administration ( FDA ) treatment pediatric patient 1 21 year old relapse acute lymphoblastic leukemia ( ALL ) least 2 prior treatment regimen . This research study clofarabine use advanced cancer person drug longer effective reliable effective treatment available . The purpose study find answer follow research question : 1 . What large dose clofarabine safely administer IV infusion ( least 2 hour ) week 3 week ( day 1 , 8 15 ) follow 1 week rest repeat every 28 day ? 2 . What side effect clofarabine give schedule ? 3 . How much clofarabine blood specific time administration body get rid drug ? Once MTD/RP2D establish , patient enrol MTD/RP2D regardless PK data cardiac assessment do every cycle . 4 . Will clofarabine help treat specific cancer ?</brief_summary>
	<brief_title>Clofarabine Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Have pathologic diagnosis advance solid tumor After MTD establish , patient must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion Be great equal 18 year old Not eligible therapy higher curative potential Have Karnofsky Performance Status ( KPS ) great equal 70 Have estimate life expectancy great equal 12 week Have negative serum urine pregnancy test within 7 day study enrollment ( patient female childbearing potential ) Male female patient fertile must agree use effective barrier method birth control ( latex condom , diaphragm , cervical cap , etc . ) avoid pregnancy Sign write informed consent form Able comply study procedure followup examination Have adequate organ function indicate follow laboratory value , obtain within 2 week prior registration : ANC : great equal 1.5 × 10 9th/L ; Platelets : great equal 100 × 10 9th/L ; Serum bilirubin : le 2.0 mg/dL ; AST ALT : less 3 x ULN ( Institutional Upper Limit Normal ) without liver involvement OR le 5 x ULN ( * ) liver involvement ; Serum creatinine : le 2.0 mg/dL ; Echocardiogram shorten fraction : great equal 28 % ( Not pharmacologic support ) ; Ejection fraction great equal 50 % ( Not pharmacologic support ) . Received previous treatment clofarabine . Have active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . Prior malignancy le 2year diseasefree interval , except adequately treat basal cell squamous cell skin cancer ; situ cancer cervix . Are pregnant lactating . Have psychiatric disorder ( ) would interfere consent , study participation , followup . Have receive chemotherapy , major surgery , irradiation , whether conventional investigational , &lt; 4 week enrollment study ( 6 week mitomycinC nitrosourea ) and/or recover acute toxicity previous therapy prior enrollment . Have severe concurrent disease , , judgment investigator , would make patient inappropriate entry study ( eg , uncontrolled severe insulindependent diabetes , uncontrolled hypertension , transient ischemic attack , uncontrolled symptomatic coronary artery disease , etc. ) . Have receive prior radiation therapy great equal 25 % bone marrow ( eg , whole pelvic irradiation allow ) recover acute side effect radiotherapy . Have receive prior radiation therapy mediastinal region . Have bronchoalveolar pattern evident chest xray . Have symptomatic untreated central nervous system ( CNS ) metastases .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>CLO151</keyword>
	<keyword>Clolar</keyword>
	<keyword>Pediatric ALL AML</keyword>
	<keyword>Adult ALL AML MDS</keyword>
</DOC>